Exelixis, Inc. (EXEL): R&D Expense
$825.00M
Year ended 2026-01-02, Fiscal 2025
$824.32M
Trailing 12 months to 2026-07-03
-2.6%
3-year compound annual growth
+8.5%
5-year compound annual growth
+24.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $825.00M | -9.4% | 2026-02-10, From 2025-01-04 |
| 2025-01-03, Fiscal 2024 | $910.41M | -12.8% | 2026-02-10, From 2023-12-30 |
| 2023-12-29 | $1.04B | +17.1% | 2026-02-10, From 2022-12-31 |
| 2022-12-30 | $891.81M | +28.6% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $693.72M | +26.6% | 2024-02-06, From 2021-01-02 |
| 2021-01-01, Fiscal 2020 | $547.85M | +62.6% | 2023-02-07, From 2020-01-04 |
| 2020-01-03, Fiscal 2019 | $336.96M | +84.9% | 2022-02-18, From 2018-12-29 |
| 2018-12-28 | $182.26M | +62.5% | 2021-02-11, From 2018-01-01 |
| 2017-12-29 | $112.17M | +16.9% | 2020-02-25, From 2016-12-31 |
| 2016-12-30 | $95.97M | -0.4% | 2019-02-22, From 2016-01-02 |
| 2016-01-01, Fiscal 2015 | $96.35M | -49.0% | 2018-02-26, From 2015-01-03 |
| 2014-12-31 | $189.10M | +5.8% | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | $178.76M | +38.7% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $128.88M | -17.8% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $156.84M | -25.6% | 2014-02-20, From 2011-01-01 |
| 2010-12-31 | $210.68M | -10.2% | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | $234.70M | n/a | 2012-02-22, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $825.00M | -9.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $187.52M | -3.1% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.13B | -31.1% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.02B | +38.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Novavax Inc (NVAX) | 2025-12-31 | $342.32M | -12.5% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $166.13M | -4.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗